线性螯合剂对比剂给药后的钆沉积与欧洲药品管理局的建议
欧洲药品管理局药物警戒风险评估委员会因钆沉积潜在风险建议暂停部分线性螯合剂钆对比剂上市许可,人用药品委员会重新评估后确认最终意见。本文概述可用的钆对比剂并总结钆沉积的最新证据,对现有科学证据的优势与局限进行批判性评价。
要点
- 欧洲药品管理局建议暂停四种线性钆对比剂的部分欧盟上市许可。
- 脑MRI提示的钆沉积已通过质谱法证实。
- 目前无明确临床证据表明钆沉积导致神经毒性。
核心结论
- 欧洲药品管理局最终意见确认暂停部分线性螯合剂钆对比剂上市许可,钆沉积的长期安全性仍不明确。
研究设计与样本
- 本文为社论,概述可用的钆对比剂并总结钆沉积的最新证据,对现有科学证据进行批判性评价。
关键影像表现/征象
- 脑MRI提示钆沉积的发现已通过质谱法证实。
局限性
- 目前关于钆沉积的科学证据存在若干方法学局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
UNLABELLED: The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) earlier this year recommended to suspend some marketing authorisations for Gadolinium Containing Contrast Agents (GCCAs) based on linear chelators due to the potential risk of gadolinium retention in the human body. These recommendations have recently been re-evaluated by EMA's Committee for Medicinal Products for Human Use (CHMP), and confirmed the final opinion of the European Medicines Agency. This editorial provides an overview of the available GCCAs and summarises the recent evidence of gadolinium retention. Moreover, a critical appraisal of the strengths and limitations of the scientific evidence currently available on gadolinium retention is given.
KEY POINTS: • EMA recommended suspension of some EU marketing authorisations of four linear GCCAs. • Brain MRI findings indicating gadolinium retention have been confirmed by mass spectrometry. • Current scientific evidence for gadolinium retention has several methodological limitations. • No clear clinical evidence exists indicating that gadolinium retention causes neurotoxicity. • Long-term safety of GCCAs, however, remains unclear.
引用
- Dekkers IA, Roos R, van der Molen AJ, et al. Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol. 2017. PMID: 29063255. doi:10.1007/s00330-017-5065-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。